Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helio S Sader

Showing results (261-270 of 420) with videos related to

Pageof 42
Sort By:
Antibiotics (Basel, Switzerland)|June 25, 2025
Activity of β-Lactamase Inhibitor Combinations Against Enterobacterales Isolated from Patients with Intra-Abdominal Infection from United States Medical Centres (2019-2023)Helio S Sader, John H Kimbrough, Marisa L Winkler, et al.
Journal of Clinical Microbiology|July 3, 2023
Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 μg/mL), a Novel β-Lactam/β-Lactamase Inhibitor CombinationMichael D Huband, Kelley A Fedler, Helio S Sader, et al.
Jac-Antimicrobial Resistance|August 25, 2021
Characterization of <i>Enterobacter cloacae</i> and <i>Citrobacter freundii</i> species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agentsHelio S Sader, Rodrigo E Mendes, Timothy B Doyle, et al.
The Journal of Antimicrobial Chemotherapy|June 15, 2018
Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosaHelio S Sader, Robert K Flamm, Glenn E Dale, et al.
The Journal of Antimicrobial Chemotherapy|June 22, 2019
Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitalsMariana Castanheira, Timothy B Doyle, Caitlin J Smith, et al.
Infection Control and Hospital Epidemiology|March 1, 2002
Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in BrazilRosangela F Cereda, Ana C Gales, Suzane Silbert, et al.
The Journal of Antimicrobial Chemotherapy|January 3, 2018
Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16)Michael A Pfaller, Helio S Sader, Mariana Castanheira, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamasesHelio S Sader, Paul R Rhomberg, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2017
Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014Helio S Sader, Mariana Castanheira, Rodrigo E Mendes, et al.
Antimicrobial Agents and Chemotherapy|April 8, 2015
Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strainsMariana Castanheira, Janet C Mills, Sarah E Costello, et al.
Pageof 42

Showing results (261-270 of 420) with videos related to

Sort By:
Pageof 42
Antibiotics (Basel, Switzerland)|June 25, 2025
Activity of β-Lactamase Inhibitor Combinations Against Enterobacterales Isolated from Patients with Intra-Abdominal Infection from United States Medical Centres (2019-2023)Helio S Sader, John H Kimbrough, Marisa L Winkler, et al.
Journal of Clinical Microbiology|July 3, 2023
Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 μg/mL), a Novel β-Lactam/β-Lactamase Inhibitor CombinationMichael D Huband, Kelley A Fedler, Helio S Sader, et al.
Jac-Antimicrobial Resistance|August 25, 2021
Characterization of <i>Enterobacter cloacae</i> and <i>Citrobacter freundii</i> species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agentsHelio S Sader, Rodrigo E Mendes, Timothy B Doyle, et al.
The Journal of Antimicrobial Chemotherapy|June 15, 2018
Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosaHelio S Sader, Robert K Flamm, Glenn E Dale, et al.
The Journal of Antimicrobial Chemotherapy|June 22, 2019
Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitalsMariana Castanheira, Timothy B Doyle, Caitlin J Smith, et al.
Infection Control and Hospital Epidemiology|March 1, 2002
Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in BrazilRosangela F Cereda, Ana C Gales, Suzane Silbert, et al.
The Journal of Antimicrobial Chemotherapy|January 3, 2018
Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16)Michael A Pfaller, Helio S Sader, Mariana Castanheira, et al.
The Journal of Antimicrobial Chemotherapy|March 24, 2017
WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamasesHelio S Sader, Paul R Rhomberg, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2017
Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014Helio S Sader, Mariana Castanheira, Rodrigo E Mendes, et al.
Antimicrobial Agents and Chemotherapy|April 8, 2015
Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strainsMariana Castanheira, Janet C Mills, Sarah E Costello, et al.
Pageof 42